Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

AbbVie

Viatris

High dividend yields plus low valuations could be just the ticket for income-seeking investors.

3 Great Dividend Stocks That Are Simply Too Cheap to Ignore

Elanco Animal Health Inc

Jazz Pharmaceuticals

Johnson & Johnson

Moderna

Pfizer

Pharmaceutical stocks have many benefits, particularly when their products are in demand. And in 2021, that seems likely to be the case.

7 Pharmaceutical Stocks With Exciting Plans for 2021

Medical Properties Trust

With solid valuations and good dividends, these businesses will get you through the next rainy day -- or year.

3 Recession-Proof Healthcare Stocks to Buy for 2021

The company's total authorization now stands at around $6.4 billion.

Bristol Myers Squibb Adds $2 Billion to Share Repurchase Program

Novartis

Sanofi

Takeda Pharmaceutical

Pharmaceutical stocks can be a great investment in a unique niche of the market. The stocks on this list will be strong for a decade plus.

The Top 7 Pharmaceutical Stocks for the Next 10 Years

Bristol-Myers Squibb Company's (BMY) CEO Giovanni Caforio Presents at 39th Annual JPMorgan Virtual Healthcare Conference - (Transcript)

Amgen

AstraZeneca

MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL, Inc., a healthcare company whose mission is to detect cancer early, today announced collaborations with global biopharmaceutical companies Amgen (NASDAQ:AMGN), AstraZeneca (LSE/STO/Nasdaq: AZN), and Bristol Myers Squibb (NYSE: BMY) to evaluate GRAIL's methylation-based technology for the detection of minimal residual disease (MRD). Cancer MRD testing is used in clinical and research applications to detect the presence or absence of residual disease. M

GRAIL Announces Collaborations with Amgen, AstraZeneca, and Bristol Myers Squibb to Evaluate Cancer Early Detection Technology for Minimal Residual Disease

Bristol Myers Squibb Co. said Monday its board has approved an additional $2 billion of share buybacks, bringing the company's full authorization to about $6.4 billion. Shares rose 1% premarket, but have fallen 3% in the last 12 months, while the S&P 500 has gained 17%.

Bristol Myers adds $2 billion to share buyback program

NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb Announces $2 Billion Incremental Share Repurchase Authorization

Bristol Myers Squibb Announces $2 Billion Incremental Share Repurchase Authorization

An attractive price and dividend combined with tremendous growth prospects make this stock a slam-dunk buy.

My Favorite Dirt-Cheap Dividend Stock Right Now

Apple

Mastercard

Each of them should have positive catalysts in the new year.

3 Warren Buffett Stocks That Should Be Big Winners in 2021

In the latest trading session, Bristol-Myers Squibb (BMY) closed at $61.70, marking a +0.24% move from the previous day.

Bristol-Myers Squibb (BMY) Gains But Lags Market: What You Should Know

Intel

Prudential Financial

AT&T

This article is about reviewing 2020 as a complete year from the lens of dividend growth/dividend investing. My portfolio holds a large variety of exposures in a multitude of geographies, sectors and industries.

2020 Dividend Investment Report And Year-End 'Buys'

ADDING ANOTHER DRUG DISCOVERY PROJECT TO THE PORTFOLIO TRIGGERS PAYMENT TO EVOTEC HAMBURG, GERMANY / ACCESSWIRE / January 5, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company has received a US$ 6 m payment from Bristol Myers Squibb Company (NYSE:BMY) within the companies' iPSC-based neuroscience partnership. The payment follows Bristol Myers Squibb's decision to add another drug discovery project to the partnership's portfolio.

Evotec Achieves Milestone in Its Neurodegeneration Collaboration with Bristol Myers Squibb

Aptiv

Disney

Howard Hughes

Southwest Airlines

2020 has taken the market capitalizations of many strong companies to lows. That means there are some great options for cheap stocks to buy in January.

7 Cheap Stocks to Buy in January For a Quick Buck

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) as Adjuvant Treatment for....

European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) as Adjuvant Treatment for Resected Esophageal or Gastroesophageal Junction Cancer Following Chemoradiotherapy

NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb to Present at J.P. Morgan's 39th Annual Virtual Healthcare Conference

Bristol Myers Squibb to Present at J.P. Morgan's 39th Annual Virtual Healthcare Conference

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) Combined with Chemotherapy as First-Line Treatment....

European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) Combined with Chemotherapy as First-Line Treatment in Metastatic Gastric Cancer, Gastroesophageal Junction Cancer and Esophageal Adenocarcinoma

Bank of America

Warren Buffett's 3 Best Stock Picks in 2020

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Provides Update on Status of Contingent Value Rights

Bristol Myers Squibb Provides Update on Status of Contingent Value Rights

Citigroup

Enterprise Products Partners

MPLX

Simon Property Group

SPDR S&P 500 ETF Trust

W. P. Carey

2021 could be a year in which value stocks outperform. Income potential remains a key theme for 2021 and beyond, as interest rates remain at record lows.

Top 10 Undervalued High-Yield Income Stocks For 2021

Ally Financial

Alibaba

Gogo

QUALCOMM

Walgreens

Cheap stocks have always intrigued investors because we always want a bargain. So, here are seven cheap stocks to buy now.

7 Cheap Stocks That Can't Wait for 2021 

Investors need to pay close attention to Bristol-Myers Squibb (BMY) stock based on the movements in the options market lately.

Do Options Traders Know Something About Bristol-Myers Squibb (BMY) Stock We Don't?

Broadcom

Comcast

Eaton

Northrop Grumman

With 2020 mercifully ending today, many investors are evaluating portfolios for 2021.

5 BofA Securities Top Stock Picks for 2021 Also Pay Solid Dividends

The elusive conjunction of safety and growing yield is a holy grail for many investors. Seeking Alpha's quant system screens seven larger large cap biotech stocks with dividends ranging from 3.16% to 5.04%.

News for Bristol-Myers Stock (BMY)